Global Chronic Pain Treatment Market - 2023-2030

Global Chronic Pain Treatment Market - 2023-2030

Global Chronic Pain Treatment Market reached US$ 83.8 billion in 2022 and is expected to reach US$ 143.2 billion by 2030 growing with a CAGR of 7.1% during the forecast period 2023-2030. Novel strategies have evolved for the effective and safe management of chronic pain such as Radiofrequency technique, regenerative biomaterial, platelet-rich plasma, and mesenchymal stem cells; are some of the upcoming procedures that are used in chronic pain treatments.

Chronic pain is a major health condition where the pain lasts for months or years. Chronic pain mainly affects people who are already suffering from diabetes, fibromyalgia, and severe back pains. Being active and doing exercise at a younger age can control chronic pains. Pain medications can be taken by a patient if it is in a severe case.

Opioids, non-steroidal anti-inflammatory drugs(NSAIDs), anticonvulsants, and antidepressants are the most commonly used drugs for treating chronic pain. Neurostimulation devices and analgesic infusions are the most commonly used devices for treating chronic pain. Furthermore, significant growth drivers such as the increasing prevalence of chronic diseases, growing geriatric population, technical advancements, rising clinical trials, and increasing FDA approvals give rise to future market growth.

Market Dynamics

Increasing Geriatric Population Drives the Growth of the Global Chronic Pain Treatment Market Growth

The rising population of elderly and old people is a major growth factor in the chronic pain treatment market. The geriatric population is more prone to chronic pain disorders like arthritis, cancers, chronic back pain and neuropathic pains. For instance, according to ncbi.nih.gov, an article entitled multidisciplinary management of chronic pain in elderly oncology patients published on Sep 22 2022, states that chronic pain is one of the most common and most bothersome symptoms in cancer patients, which occurs often in the elderly population.

Pain in cancer patients results from complex pathological mechanisms, including cellular, tissue, and systemic changes caused by growing tumor tissue, as well as changes associated with a progressive, debilitating disease. Chronic pain can be caused directly by cancer treatment and breakthrough pains. Patients with neuropathic pain, which is especially frequent in elderly individuals complain about the burning, tingling, or numbness in a specific area of the skin surface with attacks of sudden and wrenching pain along the limb.

Technical Advancement of the Chronic Pain Devices is Boosting the Future Market Growth

The chronic pain treatment market has witnessed significant growth due to various technological advancements. Many key players play a major role in these advancements by launching new products and services. This new product can rise the productivity and efficacy of patients who suffered from chronic illness.

For instance, on May 16, 2023, Abbot announced that its spinal cord stimulation (SCS) devices has approved by the U.S Food and Drug Administration. This SCS device is used for the treatment of chronic back pain. It is mainly utilized by people who have not or not eligible to perform surgical back pain. This labeling expansion was supported by results from the distinct study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities, and emotional well-being in people with chronic back pain.

Significant Challenges Possessed with Chronic Arthritis Pain are Expected to Hamper Global Chronic Pain Treatment Market

According to Everyday Health journal, a journal entitled The Risks of Untreated Rheumatoid Arthritis published on July 7, 2022, if the arthritis is left untreated, then it may cause complications like joint pains. There is a high risk of getting heart disease for arthritis patients. This inflammation can also contribute to the narrowing of your blood vessels which allows plaque to build up.

According to a study published in May 2022 in Arthritis & Rheumatology, the link between Rheumatoid arthritis and heart problems increases the importance of monitoring and managing heart disease risk factors such as high blood pressure, high cholesterol, smoking, diabetes, and being sedentary. Overall, the more advanced your arthritis, the greater risk for heart damage.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the chronic pain treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of chronic pain disorders and initiation of treatment for patients. As a result, some chronic pain cases may have been diagnosed at later stages, potentially affecting treatment outcomes.

Also, to minimize the risk of COVID-19 transmission, healthcare providers implemented changes in treatment delivery, such as reducing in-person clinic visits, increasing telemedicine consultations, and modifying treatment schedules. These changes have impacted the overall patient experience and the management of chronic pain treatment. Therefore, owing to the above factors, the chronic pain treatment market is expected to be moderately affected over the forecast period.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of chronic pain diseases such as arthritis and chronic back pain. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with chronic pain diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict can result in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity led to delays in diagnosis, inadequate treatment options, and suboptimal disease management for chronic pain disorders patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients’ continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their chronic pain disorder treatment.

For more details on this report –Request for Sample

Segment Analysis

The global chronic pain treatment market is segmented based on product type, indication, distribution channel, and region.

Owing to the Increasing Prevalence of Chronic Diseases like Migraines, Rising Clinical Trials, the Drug Segment Accounted for Approximately 42.3% of the Chronic Pain Treatment Market Share

Some medications commonly prescribed to manage depression and prevent epileptic seizures have been found to help relieve chronic pain. This is true especially for chronic nerve pain. They help relieve back pain, fibromyalgia and diabetes-related nerve pain, known as diabetic neuropathy. Because chronic pain often worsens depression, antidepressants offer the extra benefit of treating mood symptoms.

For instance, on Feb 27, 2023, Scilex Holding Company announced the commercial launch of an oral solution ELYXYBTM in the U.S., strengthening its leadership position in non-opioid pain management. ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine. There is strong evidence for the use of NSAIDs as a first-line treatment for migraine. Celecoxib is in the same class of agents which is fast acting, and has the potential to have the lowest side effects of all NSAIDs.

Geographical Analysis

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure

The North American region is anticipated to experience growth in the field of chronic pain treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems.

These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in chronic pain treatment throughout the forecast period.

For instance, On Oct 14, 2022, Nevro Corporation announced that the Senza HFX iQ spinal cord stimulation system has received approval from U.S FDA. The company further decides a limited release of Senza HFX iQ in the quarter. Additionally, US FDA approval for HFX iQ, Nevro has submitted the technology for approval in Europe too. The system is comprised of the HFX iQ implantable pulse generator (IPG), HFX trial stimulator, charger and HFX app, and will launch with algorithms specifically for treating chronic back and leg pain, including non-surgical back pain (NSBP) and painful diabetic neuropathy (PDN).

Competitive Landscape

The major global players in the market include Pfizer Inc., Abbott Laboratories, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Sanofi SA, Teva Pharmaceutical Industries Ltd, Baxter International, Merck & Co. Inc, Boston Scientific Corporation

Why Purchase the Report?
• To visualize the global chronic pain treatment market segmentation based on the product type, indication, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic pain treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic pain treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies